{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:49:08Z","timestamp":1791571748691,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clml.2025.08.002","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T02:45:37Z","timestamp":1754621137000},"page":"e1-e11.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Utilization of Carfilzomib (Once or Twice Weekly) Initiated in Patients After a First Relapse Between 2017 and 2022 in France: An Analysis From a Large-Scale Epidemiology of Multiple MYeloma (EmmY) Cohort"],"prefix":"10.1016","volume":"26","author":[{"given":"Cyrille","family":"Hulin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Belhadj Merzoug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Royer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Caillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Bobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0460-0658","authenticated-orcid":false,"given":"Margaret","family":"Macro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5904-1286","authenticated-orcid":false,"given":"Laure","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mammoun","family":"Dib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique Orsini","family":"Piocell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"Benramdane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Calmettes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Chalopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Garlant\u00e9zec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4636-7361","authenticated-orcid":false,"given":"Ga\u00eblle","family":"D\u00e9sam\u00e9ricq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakima","family":"Mechiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Decaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.08.002_bib0001","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2025.08.002_bib0002","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2020)","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2025.08.002_bib0003","series-title":"KYPROLIS (carfilzomib) - My\u00e9lome multiple","year":"2021"},{"key":"10.1016\/j.clml.2025.08.002_bib0004","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"NCCN Guidelines\u00ae insights: Multiple myeloma, version 3.2022","volume":"20","author":"Callander","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2025.08.002_bib0005","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.08.002_bib0006","article-title":"Multiple Myeloma, Version 1.2025, NCCN clinical practice guidelines in oncology","author":"Kumar","year":"2024","journal-title":"Mult Myeloma"},{"key":"10.1016\/j.clml.2025.08.002_bib0007","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study","volume":"19","author":"Moreau","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.08.002_bib0008","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024013101","article-title":"A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed\/refractory multiple myeloma","author":"Dimopoulos","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.08.002_bib0009","unstructured":"Intergroupe Francophone du My\u00e9lome (IFM). IFM recommendations on Covid-19. 2020. https:\/\/www.myelome.fr\/PressRoom\/57\/2020-11-03-Flash-info-COVID-19.html Accessed November 8, 2024."},{"key":"10.1016\/j.clml.2025.08.002_bib0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.46989\/001c.121371","article-title":"The EMMY longitudinal, cohort study: real-world data to describe multiple myeloma management and outcomes as more therapeutic options emerge","volume":"6","author":"Decaux","year":"2024","journal-title":"Clin Hematol Int"},{"key":"10.1016\/j.clml.2025.08.002_bib0011","unstructured":"International Myeloma Working Group. International Myeloma Working Group (IMWG). Uniform Response Criteria for Multiple Myeloma. International Myeloma Working Group (IMWG). 2021. https:\/\/www.myeloma.org\/resourcelibrary\/international-myeloma-working-group-imwg-uniformresponse-criteria-multiple Accessed January, 12 2025."},{"key":"10.1016\/j.clml.2025.08.002_bib0012","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jha2.828","article-title":"Real-life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: the CARMYN study","volume":"5","author":"Laribi","year":"2024","journal-title":"EJHaem"},{"key":"10.1016\/j.clml.2025.08.002_bib0013","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/jha2.595","article-title":"Real-world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel","volume":"4","author":"Leleu","year":"2023","journal-title":"EJHaem"},{"key":"10.1016\/j.clml.2025.08.002_bib0014","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/jha2.946","article-title":"Carfilzomib use in patients with relapsed\/refractory multiple myeloma in France: a national retrospective cohort study","volume":"5","author":"Hulin","year":"2024","journal-title":"EJHaem"},{"key":"10.1016\/j.clml.2025.08.002_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100003","article-title":"Real-world comparison of daratumumab-based regimens in relapsed\/refractory multiple myeloma using health record data","volume":"1","author":"Derman","year":"2024","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.clml.2025.08.002_bib0016","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1182\/blood-2023-178082","article-title":"Carfilzomib-pomalidomide-dexamethasone in anti-CD38 antibodies and lenalidomide relapse\/refractory multiple myeloma: a real life monocentric cohort","volume":"142","author":"Debureaux","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.08.002_bib0017","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/jha2.774","article-title":"The real-world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies","volume":"4","author":"Szabo","year":"2023","journal-title":"EJHaem"},{"key":"10.1016\/j.clml.2025.08.002_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215311","article-title":"Real-world use and effectiveness of Carfilzomib plus dexamethasone in relapsed\/refractory multiple myeloma in Europe","volume":"14","author":"Terpos","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2025.08.002_bib0019","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.08.002_bib0020","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with Carfilzomib, Lenalidomide, and Dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.08.002_bib0021","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2025.08.002_bib0022","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/bjh.17541","article-title":"Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy","volume":"194","author":"Quach","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.08.002_bib0023","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","article-title":"Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study","volume":"7","author":"Usmani","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.08.002_bib0024","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/10428194.2024.2322030","article-title":"An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study","volume":"65","author":"Perrot","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2025.08.002_bib0025","doi-asserted-by":"crossref","first-page":"e786","DOI":"10.1097\/HS9.0000000000000786","article-title":"Carfilzomib, Pomalidomide, and dexamethasone As second-line therapy for lenalidomide-refractory multiple myeloma","volume":"6","author":"Sonneveld","year":"2022","journal-title":"Hemasphere."},{"key":"10.1016\/j.clml.2025.08.002_bib0026","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1182\/bloodadvances.2020001965","article-title":"Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and\/or refractory multiple myeloma","volume":"4","author":"Facon","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.08.002_bib0027","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s00277-021-04522-y","article-title":"Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France - a cohort study using the French National Healthcare database (SNDS)","volume":"100","author":"Touzeau","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2025.08.002_bib0028","doi-asserted-by":"crossref","DOI":"10.1007\/s12325-025-03248-x","article-title":"Treatment patterns, goals, and decision-making criteria for second- and third-line therapies for multiple myeloma in Germany","author":"Steinmetz","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.clml.2025.08.002_bib0029","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2015-05-643320","article-title":"Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma","volume":"126","author":"Shah","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.08.002_bib0030","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/10428194.2020.1832672","article-title":"Efficacy and safety of weekly carfilzomib (70 mg\/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies","volume":"62","author":"Leleu","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2025.08.002_bib0031","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1182\/bloodadvances.2024013101","article-title":"A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed\/refractory multiple myeloma","volume":"8","author":"Dimopoulos","year":"2024","journal-title":"Blood Adv"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T15:15:07Z","timestamp":1772896507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2152265025002678"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.08.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Utilization of Carfilzomib (Once or Twice Weekly) Initiated in Patients After a First Relapse Between 2017 and 2022 in France: An Analysis From a Large-Scale Epidemiology of Multiple MYeloma (EmmY) Cohort","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}